
7. Literaturverzeichnis

1. Scaffidi C, Fulda S, Srivansan A, et al. Two CD95 (APO-1/Fas) signalling pathways. *EMBO J.* 1998;17:1675-1687.
2. Hengartner MO, Horwitz HR. Programmed cell death in *Caenorhabditis elegans*. *Curr Opin Genet Dev.* 1994;4:581-586.
3. Horvitz HR, Ellis HM, Sternberg PW. Programmed cell death in nematode development. *Neurosci Commentaries.* 1982;1:56-65.
4. Ellis HM, Horvitz HR. Genetic control of programmed cell death in the nematode *C. elegans*. *Cell.* 1986;44:817-829.
5. Hengartner MO, Ellis HM, Horvitz HR. *Caenorhabditis elegans* gene *ced-9* protects cells from programmed cell death. *Nature.* 1992;356:494-499.
6. Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. *Nature.* 1995;376:37-43.
7. Thornberry NA, Rano TA, Peterson EP, et al. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. *J Biol Chem.* 1997;272:17907-17911.
8. Thornberry NA, Lazebnik Y. Caspases: Enemies within. *Science.* 1998;281:1312-1316.
9. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. *Nature.* 1988;335:440-442.
10. Oltvai ZN, Millman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homologue, Bax, that accelerates programmed cell death. *Cell.* 1993;74:609-619.
11. Eskes R, Desagher S, Antonsson B, Martinou JC. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. *Mol Cell Biol.* 2000;20:929-935.

12. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. *Proc Natl Acad Sci USA*. 1998;95:4997-5002.
13. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to *C. elegans* CED-4, participates in cytochrome *c*-dependent activation of Caspase-3. *Cell*. 1997;90:405-413.
14. Cain K, Bratton SB, Langlais C, et al. Apaf-1 oligomerizes into biologically active approximately 700-kDa and inactive approximately 1.4-MDa apoptosome complexes. *J Biol Chem*. 2000;275:6067-6070.
15. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: Integrating mammalian biology. *Cell*. 2001;104:487-501.
16. Banner DW, D'Arcy A, Janes W, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF β complex: Implications for TNF receptor activation. *Cell*. 1993;73:431-445.
17. Nagata S. Apoptosis by death factor. *Cell*. 1997;88:355-365.
18. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. *Cell*. 1993;74:845-853.
19. Scaffidi C, Krammer PH, Peter ME. Isolation and analysis of components of CD95 (APO-1/Fas) death-inducing signaling complex. *Methods in Enzymology*. 1999;17:287-291.
20. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D. A novel protein that interacts with the death domain of Fas/APO-1 contains a sequence motif related to the death domain. *J Biol Chem*. 1995;270:7795-7798.
21. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. *Cell*. 1995;81:505-512.
22. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT-1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. *Cell*. 1996;85:803-815.

-
23. Medema JP, Scaffidi C, Kischkel FC, et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). *EMBO J.* 1997;16:2794-2804.
 24. Muzio M, Chinnaiyan AM, Kischkel FC, et al. Flice, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/Apo-1) Death-inducing signaling complex. *Cell.* 1996;85:817-827.
 25. Martin DA, Siegel RM, Zheng L, Lenardo MJ. Membrane oligomerization and cleavage activates the Caspase-8 (FLICE/MACH-1) death signal. *J Biol Chem.* 1998;273:4345-4349.
 26. Peter ME, Scaffidi C, Medema JP, Kischkel FC, Krammer PH. The death receptors. In: Kumar S, ed. *Apoptosis, Problems and Diseases.* Heidelberg: Springer; 1998.
 27. Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ. BID: A novel BH3 domain-only death agonist. *Genes Dev.* 1996;10:2859-2869.
 28. Kudla G, Montessuit S, Eskes R, et al. The destabilization of lipid membranes induced by the C-terminal fragment of caspase 8-cleaved bid is inhibited by the N-terminal fragment. *J Biol Chem.* 2000;275:22713-22718.
 29. Slee EA, Keogh SA, Martin SJ. Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalyzed by caspase-3: a potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release. *Cell Death Differ.* 2000;7:556-565.
 30. Irmeler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. *Nature.* 1997;388:190-195.
 31. Hu S, Vincenz C, Ni J, Gentz R, Dixit VM. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1 and CD95-induced apoptosis. *J Biol Chem.* 1997;272:17255-17257.
 32. Srinivansula SM, Ahmad M, Otilie S, et al. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. *J Biol Chem.* 1997;272:18542-18545.
 33. Moriishi K, Huang DC, Cory S, Adams JM. Bcl-2 family members do not inhibit apoptosis by binding the caspase activator Apaf-1. *Proc Natl Acad Sci U S A.* 1999;96:9683-9688.

34. Newmeyer DD, Bossy-Wetzel E, Kluck RM, Wolf BB, Beere HM, Green DR. Bcl-XI does not inhibit the function of Apaf-1. *Cell Death Differ.* 2000;7:402-407.
35. Liston P, Roy N, Tamai K, et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. *Nature.* 1996;379:349-353.
36. Uren AG, Pakusch M, Hawkins CJ, Puls KL, Vaux DL. Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor associated factors. *Proc Natl Acad Sci USA.* 1996;93:4974-4978.
37. Rothe M, Pan M-G, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. *Cell.* 1995;83:1243-1252.
38. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. *Nature.* 1997;388:300-304.
39. Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC. The cIAP-1 and cIAP-2 proteins are direct inhibitors of specific caspases. *EMBO J.* 1997;16:6914-6925.
40. Deveraux QL, Roy N, Stennicke HR, et al. IAPs block apoptotic events induced by caspase-8 and cytochrom *c* by direct inhibition of distinct caspases. *EMBO J.* 1998;17:2215-2223.
41. Clem RJ, Miller LK. Control of programmed cell death by the baculovirus genes p53 and iap. *Mol Cell Biol.* 1994;14:5212-5222.
42. Takahashi R, Deveraux QL, Tamm I, et al. A single BIR domain of XIAP sufficient for inhibiting caspases. *J Biol Chem.* 1998;273:7787-7790.
43. Lorick KL, Jensen JP, Fang S, Ong AM, Hatakeyama S, Weissman AM. Ring fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. *Proc Natl Acad Sci USA.* 1999;96:11364-11369.
44. Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. *Science.* 2000;288:874-877.

-
45. Huang H, Joazeiro CA, Bonfoco E, Kamada S, Levenson JD, Hunter T. The inhibitor of apoptosis cIAP2, functions as a ubiquitin-protein ligase and promotes *in vitro* monoubiquitination of Caspase 3 and 7. *J Biol Chem.* 2000;275:26661-26664.
 46. Verhagen AM, Ekert PG, Pakusch M, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. *Cell.* 2000;102:43-53.
 47. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. *Cell.* 2000;102:33-42.
 48. Srinivansula SM, Datta P, Fan X-J, Fernandes-Alnemri T, Huang Z, Alnemri ES. Molecular determinants of the caspase-promoting activity of SMAC/DIABLO and its role in the death receptor pathway. *J Biol Chem.* 2000;275:36152-36157.
 49. Ekert PG, Silke J, Hawkins CJ, Verhagen AM, Vaux DL. DIABLO promotes apoptosis by removing MIHA/XIAP from processed Caspase-9. *J Cell Biol.* 2001;152:483-490.
 50. Dürkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. *Cell.* 1992;68:421-427.
 51. Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Reed-Sternberg cells of Hodgkin's disease and a subset of normal lymphoid cells. *Nature.* 1982;299:65-67.
 52. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. *Blood.* 1985;66:848-858.
 53. Pizzolo G, Vinante F, Morosato L, et al. High serum levels of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor for progression of AIDS. *AIDS.* 1994;8:741-745.

-
54. Gedrich RW, Gilfillan MC, Duckett CS, Van Dongen JL, Thompson CB. CD30 contains two binding sites with different specificities for members of the tumor necrosis factor-associated factor family of signal transducing proteins. *J Biol Chem.* 1996;271:12852-12858.
 55. Rothe M, Wong SC, Henzel WJ, Goeddel DV. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. *Cell.* 1994;78:681-692.
 56. Boucher L-M, Marengère LEM, Lu Y, Thukral S, Mak TW. Binding sites of cytoplasmic effectors TRAF1, 2, 3 on CD30 and other members of the TNF receptor superfamily. *Biochem Biophys Res Commun.* 1997;233:592-600.
 57. Devergne O, Hatzivassiliou E, Izumi KM, et al. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: Role in NF- κ B activation. *Mol Cell Biol.* 1996;16:7098-7108.
 58. Rothe M, Sarma V, Dixit VM, Goeddel DV. TRAF2-mediated activation of NF- κ B by TNF receptor 2 and CD40. *Science.* 1995;269:1424-1427.
 59. Nakano H, Oshima H, Chung W, et al. TRAF5, an activator of NF- κ B and putative signal transducer for the lymphotoxin- β receptor. *J Biol Chem.* 1996;271:14661-14664.
 60. Malinin NL, Boldin MP, Kovalenko AV, Wallach D. MAP3K-related kinase involved in NF- κ B induction by TNF, CD95 and IL-1. *Nature.* 1997;385:540-544.
 61. Régnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M. Identification and characterization of an I κ B kinase. *Cell.* 1997;90:373-383.
 62. Lee SY, Reichlin A, Santana A, Sokol KA, Nussenzweig MC, Choi Y. TRAF2 is essential for JNK but not NF- κ B activation and regulates lymphocyte proliferation and survival. *Immunity.* 1997;7:703-713.
 63. Yeh W-C, Shahinian A, Speiser D, et al. Early lethality, functional NF- κ B activation and increased sensitivity to TNF-induced cell death in TRAF2 deficient mice. *Immunity.* 1997;7:715-725.

-
64. Duckett CS, Gedrich RW, Gilfillan MC, Thompson CB. Induction of nuclear factor κ B by the CD30 receptor is mediated by TRAF1 and TRAF2. *Mol Cell Biol.* 1997;17:1535-1542.
 65. Arch RH, Thompson CB. 4-1BB and OX40 are members of the (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor κ B. *Mol Cell Biol.* 2001;18:558-565.
 66. Song HY, Régnier CH, Kirschning CJ, Goeddel DV, Rothe M. Tumor necrosis factor (TNF)-mediated kinase cascades: Bifurcation of nuclear factor- κ B and c-Jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor-2. *Proc Natl Acad Sci U S A.* 1997;94:9792-9796.
 67. Opipari jr AW, Boguski MS, Dixit VM. The A20 cDNA induced by Tumor Necrosis Factor α encodes a novel type of zinc finger protein. *J Biol Chem.* 1990;265:14705-14708.
 68. Lee SY, Lee SY, Choi Y. TRAF-interacting protein (TRIP): A novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF- κ B activation. *J Exp Med.* 1997;185:1275-1285.
 69. Rothe M, Xiong J, Shu H-B, Williamson K, Goddard A, Goeddel DV. I-TRAF is a novel TRAF-interacting protein that regulates TRAF-mediated signal transduction. *Proc Natl Acad Sci U S A.* 1996;93:8241-8246.
 70. Cheng G, Baltimore D. TANK, a co-inducer with TRAF2 of TNF- and CD40L-mediated NF- κ B activation. *Genes and Dev.* 1996;10:963-973.
 71. Nomura F, Kawai T, Nakanishi K, Akira S. NF- κ B activation through IKK- β -dependent I-TRAF/TANK phosphorylation. *Genes to cells.* 2000;5:191-202.
 72. Wissing D, Mouritzen H, Jäättelä M. TNF-induced mitochondrial changes and activation of apoptotic proteases are inhibited by A20. *Free Radic Biol Med.* 1998;25:57-65.
 73. Opipari jr AW, Hu HM, Yabkowitz R, Dixit VM. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. *J Biol Chem.* 1992;267:12424-12427.

-
74. Fries KL, Miller WE, Raab-Traub N. Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. *J Virol.* 1996;70:8653-8659.
 75. Song HY, Rothe M, Goeddel DV. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF- κ B activation. *Proc Natl Acad Sci USA.* 1996;93:6721-6725.
 76. Hershko A, Ciechanover A. The ubiquitin system. *Annu Rev Biochem.* 1998;67:425-479.
 77. Bonifacino JS, Weissman AM. Ubiquitin and the control of protein fate in the secretory and endocytic pathways. *Annu Rev CellDev Biol.* 1998;14:19-57.
 78. Hicke L. Ubiquitin-dependent internalization and down-regulation of plasma membrane proteins. *FASEB J.* 1997;11:1215-1226.
 79. Haas AL, Siepmann TJ. Pathways of ubiquitin conjugation. *FASEB J.* 1997;11:1257-1268.
 80. Koegl M, Hoppe T, Schlenker S, Ulrich HD, Mayer TU, Jentsch S. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. *Cell.* 1999;96:635-644.
 81. Mahajan R, Delphin C, Guan T, Gerace L, Melchior F. A small ubiquitin-related polypeptide involved in targeting Ran-GAP1 to nuclear pore complex protein RanBP2. *Cell.* 1997;88:97-107.
 82. Gong L, Kamitani T, Fujise K, Caskey LS, Yeh ETH. Preferential interaction of Sentrin with a ubiquitin-conjugating enzyme, Ubc9. *J Biol Chem.* 1997;272:28198-28201.
 83. Desterro JM, Rodriguez MS, Kemp GD, Hay RT. Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1. *J Biol Chem.* 1999;274:10618-10624.
 84. Baldwin AS. The NF- κ B and I κ B proteins: New discoveries and insights. *Annu Rev Immunol.* 1996;14:649-681.
 85. Verma IM, Stevenson JK, Schwarz EM, Antwerp DV, Miyamoto S. Rel/NF- κ B/I κ B family: Intimate tales of association and dissociation. *Genes and Dev.* 1995;9:2723-2735.

-
86. Wright DA, Futcher B, Gosh P, Geha RS. Association of human Fas (CD95) with a ubiquitin-conjugating enzyme (UB-FAP). *J Biol Chem.* 1996;271:31037-31043.
 87. Alkalay I, Yaron A, Hatzubai A, Orian A, Ciechanover A, Ben Neriah Y. Stimulation-dependent I kappa B alpha phosphorylation marks the NF- kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. *Proc Natl Acad Sci U S A.* 1995;92:10599-10603.
 88. Chen ZJ, Parent L, Maniatis T. Site-specific phosphorylation of I kappa B alpha by a novel ubiquitination- dependent protein kinase activity. *Cell.* 1996;84:853-862.
 89. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF- kappa B1 precursor protein and the activation of NF-kappa B. *Cell.* 1994;78:773-785.
 90. Baeuerle PA, Baltimore D. NF- κ B: Ten years after. *Cell.* 1996;87:13-20.
 91. Tashiro K, Pando MP, Kanegae Y, Wamsley PM, Inoue S, Verma IM. Direct involvement of the ubiquitin-conjugating enzyme Ubc-9/Hus5 in the degradation of NF- κ B. *Proc Natl Acad Sci USA.* 1997;94:7862-7867.
 92. Desterro JM, Rodriguez MS, Hay RT. SUMO-1 modification of I κ B α inhibits NF- κ B activation. *Mol Cell.* 1998;2:233-239.
 93. Göttlicher M, Heck S, Doucas V, et al. Interaction of the Ubc9 human homologue with c-Jun and the glucocorticoid receptor. *Steroids.* 1996;61:257-262.
 94. Shen Z, Pardington-Purtymun PE, Comeaux JC, Moyzis RK, Chen DJ. Associations of UBE2I with RAD52, UBL1, p53 and RAD51 proteins in a yeast two-hybrid system. *Genomics.* 1996;37:183-186.
 95. Müller S, Berger M, Lehembre F, Seeler J-S, Haupt Y, Dejean A. c-Jun and p53 activity is modulated by SUMO-1 modification. *J Biol Chem.* 2000;275:13321-13329.
 96. Marafioti T, Hummel M, Foss HD, et al. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. *Blood.* 2000;95:1443-1450.

-
97. Küppers R, Rajewsky K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. *Annu Rev Immunol.* 1998;16:471-493.
 98. Jung W, Krueger S, Renner C, et al. Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources. *Mol Immunol.* 1994;31:1329-1334.
 99. Grell M, Zimmermann G, Gottfried E, et al. Induction of cell death by tumor necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. *EMBO J.* 1999;18:3034-3043.
 100. Ansieau R, Scheffrahn I, Mosialos G, et al. Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact *in vivo* with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. *Proc Natl Acad Sci USA.* 1996;93:14053-14058.
 101. Aizawa S, Nakano H, Ishida T, et al. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NF- κ B activation. *J Biol Chem.* 1997;272:2042-2045.
 102. Lee SY, Lee SY, Kandala G, Liou M-L, Liou H-C, Choi Y. CD30/TNF receptor-associated factor interaction: NF- κ B activation and binding specificity. *Proc Natl Acad Sci USA.* 1996;93:9699-9703.
 103. Horie R, Aizawa S, Nagai M, et al. A novel domain in the CD30 cytoplasmic tail mediates NF κ B activation. *Int Immunol.* 1998;10:203-210.
 104. Dürkop H, Foss H-D, Demel G, Klotzbach H, Hahn C, Stein H. Tumor necrosis factor receptor-associated factor 1 is overexpressed in Reed-Sternberg cells of Hodgkin's disease and Epstein-Barr virus-transformed lymphoid cells. *Blood.* 1999;93:1-8.
 105. Dürkop H, Hirsch B, Hahn C, Foss H-D, Stein H. Differential expression and function of A20 and TRAF1 in Hodgkin lymphoma and anaplastic large cell lymphoma and their induction by CD30 stimulation. *J Pathol.* 2002;200:214-221.

-
106. Dürkop H, Hirsch B, Hahn C, Stein H. The caspase inhibitor cIAP2 contributes to the protection of the tumor cells from apoptosis in classical Hodgkin lymphoma. *Blood*. 2003.
 107. Hahn C, Hirsch B, Jahnke D, Dürkop H, Stein H. Three new types of Apaf-1 in mammalian cells. *Biochem Biophys Res Commun*. 1999;261:746-749.
 108. Qin H, Srinivansula SM, Wu G, Fernandes-Alnemri T, Alnemri ES, Shi Y. Structural basis of procaspase-9 recruitment by the apoptotic protease-activating factor-1. *Nature*. 1999;399:549-557.
 109. Sondek J, Bohm A, Lambright DG, Hamm HE, Sigler PB. Crystal structure of a G-Protein beta gamma dimer at 2.1 Å resolution. *Nature*. 1996;379:396-374.
 110. BMERC at Boston University. <http://bmerc-www.bu.edu/bioinformatics/wdrepeat.html> . 2000.
 111. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. *Cell*. 1995;80:389-399.
 112. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-kappa B antiapoptosis: induction of TRAF1 and TRAF2 and cIAP1 and cIAP2 to suppress caspase-8 activation. *Science*. 1998;281:1680-1683.
 113. Krikos A, Laherty CD, Dixit VM. Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by κ B elements. *J Biol Chem*. 1992;267:17971-17976.
 114. Chu Z-L, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis cIAP-2 is under NF- κ B control. *Proc Natl Acad Sci USA*. 1997;94:10057-10062.
 115. Fujimoto J, Shiota M, Iwahara T, et al. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). *Proc Natl Acad Sci U S A*. 1996;93:4181-4186.

-
116. Hsu PL, Hsu SM. Autocrine growth regulation of CD30 ligand in CD30-expressing Reed-Sternberg cells: distinction between Hodgkin's disease and anaplastic large cell lymphoma. *Lab Invest.* 2000;80:1111-1119.
 117. Gruss HJ, Pinto A, Gloghini A, et al. CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues. *Am J Pathol.* 1996;149:469-481.
 118. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. *J Clin Invest.* 1997;100:2961-2969.
 119. Izban KF, Ergin M, Huang Q, et al. Characterization of NF-kappaB expression in Hodgkin's disease: Inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed Sternberg cells. *Mod Pathol.* 2001;14:297-310.
 120. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. *Oncogene.* 1999;18:943-953.
 121. Emmerich F, Meiser M, Hummel M, et al. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. *Blood.* 1999;94:3129-3134.
 122. Carpentier I, Beyaert R. TRAF1 is a TNF inducible regulator of NF- κ B activation. *FEBS Lettr.* 1999;460:246-250.
 123. Deveraux QL, Buchholtz C, Welsh K, Matsuzawa S, Stennicke HR, Salvesen GS. TRAF1 is a substrate of caspases activated during tumor necrosis factor receptor- α induced apoptosis. *J Biol Chem.* 2000.
 124. Jang HD, Chung YM, Baik JH, et al. Caspase-cleaved TRAF1 negatively regulates the antiapoptotic signals of TRAF2 during TNF-induced cell death. *Biochem Biophys Res Commun.* 2001;281:499-505.
 125. Speiser DE, Lee SY, Wong B, et al. A regulatory role for TRAF1 in antigen-induced apoptosis of T cells. *J Exp Med.* 1997;185:1777-1783.

-
126. Zhang SQ, Kovalenko AV, Cantarella G, Wallach D. Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO(IKK γ) upon receptor stimulation. *Immunity*. 2000;12:301-311.
 127. Beyaert R, Heyninck K, Van Huffel S. A20 and A20-binding proteins as cellular inhibitors of nuclear factor- kappa B-dependent gene expression and apoptosis. *Biochem Pharmacol*. 2000;60:1143-1151.
 128. Ravi R, Bedi A, Fuchs EJ, Bedi A. CD95 (Fas)-induced caspase-mediated proteolysis of NF- κ B. *Cancer Res*. 1998;58:882-886.
 129. Thomas RK, Kallenborn A, Wickenhauser C, et al. Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. *Am J Pathol*. 2002;160:1521-1528.
 130. Arenzana-Seisdedos F, Thompson J, Rodriguez MS, Bachelierie F, Thomas D, Hay RT. Inducible nuclear expression of newly synthesized I κ B α negatively regulates DNA-binding and transcriptional activities of NF- κ B. *Mol Cell Biol*. 1995;15:2689-2696.
 131. Lee JI, Burckart GJ. Nuclear factor κ B: important transcription factor and therapeutic target. *J Clin Pharmacol*. 1998;38:981-993.
 132. Müschen M, Re D, Bräuninger A, et al. Somatic mutations of the *CD95* gene in Hodgkin and Reed-Sternberg cells. *Cancer Res*. 2000;60:5640-5643.
 133. Re D, Hofmann A, Wolf J, Diehl V, Staratschek-Jox A. Cultivated H-RS cells are resistant to CD95L-mediated apoptosis despite expression of wild-type CD95. *Exp Hematol*. 2000;28:348.
 134. Wrone-Smith T, Izban KF, Ergin M, Cosar EF, Hsi ED, Alkan S. Transfection of caspase-3 in the caspase-3 deficient Hodgkin's disease cell line, KM-H2, results in enhanced sensitivity to CD95-, TRAIL-, and ARA-C-induced apoptosis. *Exp Hematol*. 2001;29:572-581.
 135. Guet C, Silvestri E, De Smaele E, Franzoso G, Vito P. c-FLIP efficiently rescues TRAF-2-/- cells from TNF-induced apoptosis. *Cell Death Differ*. 2002;9:138-144.

-
136. Niikura Y, Nonaka T, Imajoh-Ohmi S. Monitoring of Caspase-8/FLICE processing and activation upon Fas stimulation with novel antibodies against a cleavage site for Caspase-8 and its substrate, FLICE-like inhibitory protein (FLIP). *J Biochem.* 2002;132:53-62.
 137. Chai J, Du C, Wu J-W, Kyin S, Wang X, Shi Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. *Nature.* 2000;406:855-862.
 138. Ruemmele FM, Beaulieu JF, O'Connell J, Bennett MW, Seidman EG, Lentze MJ. The susceptibility to Fas-induced apoptosis in normal enterocytes is regulated on the level of cIAP1 and 2. *Biochem Biophys Res Commun.* 2002;290:1308-1314.
 139. Chhanabhai M, Krajewski S, Krajewska M, Wang HG, Reed JC, Gascoyne RD. Immunohistochemical analysis of interleukin-1beta-converting enzyme/Ced-3 family protease, CPP32/Yama/Caspase-3, in Hodgkin's disease. *Blood.* 1997;90:2451-2455.
 140. Dukers DF, Meijer CJ, ten Berge RL, Vos W, Ossenkuppele GJ, Oudejans JJ. High numbers of active caspase 3-positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin disease predict favorable clinical outcome. *Blood.* 2002;100:36-42.
 141. Saitoh H, Hinchey J. Functional heterogeneity of small ubiquitin-related protein modifiers, SUMO-1 versus SUMO-2/3. *J Biol Chem.* 2000;275:6252-6258.
 142. Becker K, Schneider P, Hofmann K, Mattmann C, Tschopp J. Interaction of Fas (Apo-1/CD95) with proteins implicated in the ubiquitination pathway. *FEBS Lettr.* 1997;412:102-106.
 143. Saltzman A, Searfoss G, Marcieau C, et al. hUBC9 associates with MEKK1 and type I TNF- α receptor and stimulates NF- κ B activity. *FEBS Lettr.* 1998;425:431-435.
 144. Ryu S-W, Chae S-K, Kim E. Interaction of Daxx, a Fas binding protein, with Sentrin and UBC9. *Biochem Biophys Res Commun.* 2000;279:6-10.
 145. Rotonda J, Nicholson DW, Fazil KM, et al. The three-dimensional structure of apopain/CPP32, a key mediator of apoptosis. *Nat Struct Biol.* 1996;3:619-625.
 146. Padgett RA, Grabowski PJ, Konarska MM, Seiler S, Sharp PA. Splicing of messenger RNA precursors. *Annu Rev Biochem.* 1986;55:1119-1150.

-
147. Adrain C, Slee EA, Harte MT, Martin SJ. Regulation of apoptotic protease activating factor-1 oligomerization and apoptosis by the WD-40 repeat region. *J Biol Chem.* 1999;274:20855-20860.
 148. Hu Y, Ding L, Spencer DM, Núñez G. WD-40 repeat region regulates Apaf-1 self-association and Procaspase-9 activation. *J Biol Chem.* 1998;273:33489-33494.
 149. Hu Y, Benedict MA, Ding L, Núñez G. Role of cytochrome *c* and dATP/ATP hydrolysis in Apaf-1-mediated caspase-9 activation and apoptosis. *EMBO J.* 1999;18:3586-3595.
 150. Srinivansula SM, Ahmad M, Fulda S, Fernandes-Alnemri T, Alnemri ES. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. *Mol Cell.* 1998;1:949-957.
 151. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome *c* and dATP-dependent formation of Apaf-1/Caspase-9 complex initiates an apoptotic protease cascade. *Cell.* 1997;91:479-489.
 152. Walke DW, Morgan JI. A comparison of the expression and properties of Apaf-1 and Apaf-1L. *Brain Research.* 2000;886:73-81.
 153. Pan G, O'Rourke K, Dixit VM. Caspase-9, Bcl-XI and Apaf-1 form a ternary complex. *J Biol Chem.* 1998;273:5841-5845.
 154. Wolf J, Kapp U, Bohlen H, et al. Peripheral blood mononuclear cells of a patient with advanced Hodgkin's Lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. *Blood.* 1996;87:3418-3428.
 155. Drexler HG, Gaedicke G, Lok MS, Diehl V, Minowada J. Hodgkin's disease derived cell lines HDLM-2 and L 428: comparison of morphology, immunological and isoenzyme profiles. *Leuk Res.* 1986;10:487-500.
 156. Kamesaki H, Fkuhara S, Tatsumi E, et al. Cytochemical, immunologic, chromosomal, and molecular genetic analysis of a novel cell line derived from Hodgkin's disease. *Blood.* 1986;68:285-292.
 157. Schaadt M, Fonatsch C, Kirchner H, Diehl V. Establishment of a malignant, Epstein-Barr-virus (EBV)-negative cell-line from the pleura effusion of a patient with Hodgkin's disease. *Blut.* 1979;38:185-190.

-
158. Diehl V, Pfreundschuh M, Fonatsch C, et al. Phenotypic and genotypic analysis of Hodgkin's disease derived cell lines: histopathological and clinical implications. *Cancer Surv.* 1985;4:399-419.
159. Fischer P, Nacheva E, Mason DY, et al. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor β -chain gene. *Blood.* 1998;72:234-240.
160. Wasik MA, Sioutos N, Tuttle M, Butmarc JR, Kaplan WD, Kadin ME. Constitutive secretion of soluble IL-2 receptor by human T-cell lymphoma xenografted into SCID mice. *Am J Pathol.* 1994;144:1089-1097.
161. Andrews PW, Damjanov I, Simon D, et al. Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2. Differentiation in vivo and in vitro. *Lab Invest.* 1984;50:147-162.
162. Quinn LA, Moore GE, Morgan RT, Woods LK. Cell lines from human colon carcinoma with unusual cell products, double minutes, and homogeneously staining regions. *Cancer Res.* 1979;39:4914-4924.
163. Schneider U, Schwenk HU, Bornkamm G. Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. *Int J Cancer.* 1977;19:621-626.
164. Jaffe ES, Harris NL, Stein H, Vardiman JW. WHO classification of tumours, pathology & genetics; tumours of the haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001.
165. Jat P, Arrand JR. In vitro transcription of two Epstein-Barr virus specified small RNA molecules. *Nucleic Acids Res.* 1982;10:3407-3425.
166. Milani S, Herbst H, Schuppan D, Hahn EG, Stein H. In situ hybridization for collagen types I, III, and IV mRNA in normal and fibrotic rat liver: evidence for predominant expression in non-parenchymal liver cells. *Hepatology.* 1989;10:84-92.

-
167. Herbst H, Steinbrecher E, Niedobitek G, et al. Distribution and phenotype of Epstein-Barr virus-harboring cells in Hodgkin's disease. *Blood*. 1992;80:484-491.
 168. Cordell J, Falini B, Erber ON, et al. Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). *Journal of Histochemistry and Cytochemistry*. 1984;32:219-229.
 169. Arcari P, Martinelli R, Salvatore F. The complete sequence of a full length cDNA for human liver glyceraldehyde-3-phosphate dehydrogenase: evidence for multiple mRNA species. *Nucleic Acids Res*. 1984;12:9179-9189.
 170. Ausubel FM, Brent R, Kingston RE, et al. *Current protocols in Molecular Biology*. In: Wiley Interscience, ed. New York: 1998.
 171. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. *Int J Cancer*. 1983;31:13-20.
 172. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. *J Immunol Methods*. 1991;139:271-279.
 173. Fields S, Song O. A novel genetic system to detect protein-protein interactions. *Nature*. 1989;340:245-246.
 174. Brent R, Ptashne M. A eukaryotic transcriptional activator bearing the DNA specificity of a prokaryotic repressor. *Cell*. 1985;43:729-736.
 175. Kawabe Y, Seki M, Seki T, et al. Covalent modification of the Werner's Syndrome gene product with the ubiquitin-related protein, SUMO-1. *J Biol Chem*. 2000;275:20963-20966.